RxDoctor Payments Data

Megan Nash, DO

Family Medicine · Slippery Rock, PANPI 1245451715

Payments from drug & device makers

$1,602in general payments, 2019–2025

Across 88 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$420
  • Novo Nordisk$392
  • GSK$222
  • Pfizer$151
  • Astellas Pharma US Inc$148
  • Lilly USA, LLC$60
  • plus $208 from 8 others

What the payments were for

  • Food & beverage$1,53796%
  • Education$654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,602 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$35,213
Medicare patients
106
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$33,971
RybelsusSemaglutide17$27,177
JardianceEmpagliflozin26$22,262
EliquisApixaban25$18,019
XareltoRivaroxaban11$14,706
Advair HfaFluticasone Propion/Salmeterol33$13,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,598
Breo ElliptaFluticasone/Vilanterol13$6,622
DuleraMometasone/Formoterol15$5,075
Celecoxib58$3,133
Gabapentin144$2,708
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$2,539
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,380
Colchicine19$2,023
Albuterol Sulfate HfaAlbuterol Sulfate58$1,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$392$61,14845 claims
Boehringer IngelheimJardiance$34$22,26226 claims
PfizerEliquis$151$18,01925 claims
GSKTrelegy Ellipta, Breo Ellipta$222$15,22127 claims
Johnson & JohnsonXarelto$40$14,70611 claims
MerckDulera$14$5,07515 claims
AbbVieSynthroid$420$1,67326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Slippery Rock

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →